| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Executive VP and COO
1 company
Vicki Kelemen last filed a Form 4 in March 2023, as Executive VP and COO at CRDF. Vicki Kelemen's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 6,053 shares of CRDF. The CRDF filings lean toward selling, a net 34,361 shares.
Vicki Kelemen has 6 Form 4 filings on record from November 2020 to March 2023, all as Executive VP and COO at Cardiff Oncology (CRDF), 2020–2023.
The 8 reported transactions were 3 option or other derivative awards, 2 option exercises, 1 open-market purchase and 1 tax withholding, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $10K and 1 sale worth about $657K.
The only open-market purchase was 960 shares of CRDF at an average $10.31 on March 23, 2021, about $10K. Twelve months later CRDF was down 76%.
The only open-market sale was 35,321 shares of CRDF at an average $18.60 on November 23, 2020, about $657K.
Shares as reported in the last Form 4 for each company; the most recent is from March 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.